Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

NCT03177460 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Prostate Adenocarcinoma
Stage III Prostate Cancer AJCC v8
Stage IIIA Prostate Cancer AJCC v8
Stage IIIB Prostate Cancer AJCC v8
Stage IIIC Prostate Cancer AJCC v8
Testosterone Greater Than 150 ng/dL

Interventions

BIOLOGICAL: Daratumumab
DRUG: FMS Inhibitor JNJ-40346527
PROCEDURE: Radical Prostatectomy

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]